A Biotech Bash - Recs and Wrecks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bash - Recs and Wrecks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (18)	8/25/1997 10:11:00 PM
From: Henry Niman	of 171

Rick, I expect LGND to begin rewarding investors now. They have quite a slate of announcements and the diabetes deal will transform the company. I expect the deal to help lead the whole sector higher. It has already begun to move on good news and LGND should begin the final stages of product approval. IR is VERY upbeat. I think that the Phase III Panretin data is as it was in Phase II which is approvable. I expect an NDA near the end of the year and LGND's first product sales (of an in-house drug) to begin next year. Targretin trials are also in the pivotol stage and I expect off label sales in diabetes to be huge (as early as the end of 1998). The diabetes deal will include LARGE up front payments (which will help buy back ALRI and limit dilution). LGND spends a lot and has its fair number of outstanding shares, but its technology is broad as is it pipeline and delivery of clinicals will get the street's attention. I've predicted 20 by the end of the year and 30 by next summer and think that LGND is on track to meet those projections. Biotechs are getting ready to move up a notch thanks to AGPH and CNTO and I expect the entire sector to benefit from upcomimg news (led by LGND).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next